Where it comes from
- Made in
- Made from angiotensin II by ACE2 and from angiotensin I by neprilysin, in heart, kidney, lung and brain
- Sent out by
- Rises on ACE inhibitors and angiotensin receptor blockers, which divert angiotensin toward it
- Acts on
- Vessels (nitric oxide release)
- Heart
- Kidney
- Lung
What it does
In medicine
- No approved medicine. It is the protective arm of the renin-angiotensin system that ACE inhibitors and sartans strengthen indirectly, by diverting angiotensin towards it 1
- It is not measured clinically: it is present in picomolar amounts and keeps degrading in the tube, so published levels depend heavily on how the blood was collected 1
Beyond the body’s own use
- A randomised trial of infusions in 343 adults hospitalised with COVID-19 was stopped early for futility: oxygen-free days did not differ from placebo 2
- The same peptide was given before and after chemotherapy in a phase 1/2 study aimed at blood counts, which is the only other setting it has been tested in people 3
- An oral formulation, the peptide held inside a cyclodextrin, has been worked on in Brazil and is active in rodents; human data remain minimal 1
- The COVID-19 idea came from ACE2 being both the enzyme that makes this peptide and the receptor the virus uses. The trial did not support it 2
Sources
- Santos et al., The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system, Physiological Reviews 2018
- Self et al., Renin-angiotensin system modulation with synthetic angiotensin (1-7) in adults with COVID-19, JAMA 2023
- Rodgers et al., Phase I/II dose escalation study of angiotensin 1-7 given around chemotherapy, Cancer Chemotherapy and Pharmacology 2006
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.